Ovid Therapeutics Inc. secured the U.S. Food and Drug Administration's fast track designation for its OV101 treatment for a nervous system disorder known as Angelman syndrome.
Angelman syndrome is a genetic disorder characterized by a variety of signs and symptoms. Characteristic features of this disorder include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety.
The company recently released positive data from its phase 1 trial and expanded the phase 2 stars study to include both adults and adolescents. Ovid expects results of the phase 2 trial in the second half of 2018.
OV101 also secured orphan drug designation for the treatment of Fragile X syndrome.
